In contrast to the EMPA‐REG OUTCOME trial, reporting non‐significant higher stroke risk (HR 1.24 [95% CI 0.92‐1.67]), we report a lower risk association for stroke (HR 0.79 [95% CI 0.61‐1.03]) with dapagliflozin compared with DPP‐4 inhibitor treatment. Here, DPP4 is linked to stroke disorder.